日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3

病例报告:IDH突变型中枢神经系统星形细胞瘤(WHO 3级)质子束治疗结束后三个月出现类似肿瘤复发的假性进展

Heggebø, Liv Cathrine; Borgen, Ida Maria Henriksen; Blakstad, Hanne; Saxhaug, Cathrine; Rønning, Pål André; Niehusmann, Pitt Frederik; Werlenius, Katja; Blomstrand, Malin; Brandal, Petter

Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial

双硫仑联合铜化疗与单纯化疗对复发性胶质母细胞瘤患者生存率的影响:一项随机临床试验

Werlenius, Katja; Kinhult, Sara; Solheim, Tora Skeidsvoll; Magelssen, Henriette; Löfgren, David; Mudaisi, Munila; Hylin, Sofia; Bartek, Jiri Jr; Strandéus, Michael; Lindskog, Magnus; Rashid, Havyan Bahroz; Carstam, Louise; Gulati, Sasha; Solheim, Ole; Bartek, Jiri; Salvesen, Øyvind; Jakola, Asgeir Store

Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden

一项在挪威和瑞典开展的随机对照试验(PRO-GLIO),旨在研究质子疗法与光子疗法治疗IDH突变型弥漫性2级和3级胶质瘤的生存率、生活质量和认知功能。

Heggebø, Liv Cathrine; Borgen, Ida Maria Henriksen; Rylander, Hillevi; Kiserud, Cecilie; Nordenmark, Tonje Haug; Hellebust, Taran Paulsen; Evensen, Morten Egeberg; Gustavsson, Magnus; Ramberg, Christina; Sprauten, Mette; Magelssen, Henriette; Blakstad, Hanne; Moorthy, Janani; Andersson, Karin; Raunert, Ingela; Henry, Thomas; Moe, Cecilie; Granlund, Carin; Goplen, Dorota; Brekke, Jorunn; Johannessen, Tor-Christian Aase; Solheim, Tora Skeidsvoll; Marienhagen, Kirsten; Humberset, Øyvind; Bergström, Per; Agrup, Måns; Dahl, Ludvig; Gubanski, Michael; Gojon, Helene; Brahme, Carl-Johan; Rydén, Isabelle; Jakola, Asgeir S; Vik-Mo, Einar O; Lie, Hanne C; Asphaug, Lars; Hervani, Maziar; Kristensen, Ingrid; Rueegg, Corina Silvia; Olsen, Inge C; Ledal, Rolf J; Degsell, Eskil; Werlenius, Katja; Blomstrand, Malin; Brandal, Petter

What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome

胶质母细胞瘤患者的生存期受哪些因素预测?一项基于人群的临床管理和预后变化研究

Fekete, B; Werlenius, K; Tisell, M; Pivodic, A; Smits, A; Jakola, A S; Rydenhag, B

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period

弥漫性IDH突变型低级别胶质瘤临床治疗管理的变化:15年间的治疗模式

Svenjeby, Caroline; Carstam, Louise; Werlenius, Katja; Bontell, Thomas Olsson; Rydén, Isabelle; Jacobsson, Julia; Dénes, Anna; Jakola, Asgeir S; Corell, Alba

Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patients

未进行组织学诊断的疑似胶质母细胞瘤患者的诊疗模式和临床结局:一项基于人群的131例连续患者的研究

Werlenius, Katja; Fekete, Boglarka; Blomstrand, Malin; Carén, Helena; Jakola, Asgeir S; Rydenhag, Bertil; Smits, Anja

Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial

双硫仑再利用联合营养性铜补充剂作为复发性胶质母细胞瘤化疗的辅助疗法(DIRECT):一项随机对照试验的研究方案

Jakola, Asgeir Store; Werlenius, Katja; Mudaisi, Munila; Hylin, Sofia; Kinhult, Sara; Bartek, Jiri Jr; Salvesen, Øyvind; Carlsen, Sven Magnus; Strandéus, Michael; Lindskog, Magnus; Löfgren, David; Rydenhag, Bertil; Carstam, Louise; Gulati, Sasha; Solheim, Ole; Bartek, Jiri; Solheim, Tora

Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells

对患者自体来源的胶质母细胞瘤干细胞进行有效的 ALECSAT 免疫治疗的决定因素

Anna Wenger, Katja Werlenius, Alexander Hallner, Fredrik Bergh Thorén, Dan Farahmand, Magnus Tisell, Anja Smits, Bertil Rydenhag, Asgeir S Jakola, Helena Carén

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia

杀伤细胞免疫球蛋白样受体和人类白细胞抗原基因型对急性髓系白血病免疫治疗疗效的影响

Bernson, E; Hallner, A; Sander, F E; Wilsson, O; Werlenius, O; Rydström, A; Kiffin, R; Brune, M; Foà, R; Aurelius, J; Martner, A; Hellstrand, K; Thorén, F B

Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells

治疗性CD20抗体诱导的活性氧会抑制自然杀伤细胞介导的针对原代CLL细胞的抗体依赖性细胞毒性作用。

Werlenius, Olle; Aurelius, Johan; Hallner, Alexander; Akhiani, Ali A; Simpanen, Maria; Martner, Anna; Andersson, Per-Ola; Hellstrand, Kristoffer; Thorén, Fredrik B